Document is current

Any future updates will be listed below

961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy

Crossref DOI link: https://doi.org/10.1136/jitc-2021-SITC2021.961

Published Online: 2021-11-10

Published Print: 2021-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark